Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
October 15, 2021

Exelixis, STORM partner to develop novel drug leads to treat cancer

Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes.

Exelixis, STORM collaborated to discover and advance novel drug leads to treat cancer. Credit: National Cancer Institute on Unsplash.